Scarica l'app Stockscreener
5.57
0.18%
-0.010
Precedente Chiudi:
$5.58
Aprire:
$5.98
Volume 24 ore:
72,373
Relative Volume:
1.24
Capitalizzazione di mercato:
$159.66M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-23.91%
1M Prestazione:
-22.96%
6M Prestazione:
+127.35%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.3306
$6.05
Intervallo di 1 settimana:
$5.22
$7.51
Portata 52W:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
5.57 | 159.95M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
504.82 | 191.54B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
212.58 | 151.94B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
629.35 | 49.28B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
125.81 | 35.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
323.37 | 31.37B | 3.17B | 642.63M | 539.81M | 10.77 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
Insider Stock Purchases: February 13, 2026 - Quiver Quantitative
Of Note: Nashville Zoo adds to board - Nashville Post
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D - TipRanks
Insight Molecular Diagnostics Signs Multiple Material Agreements - TradingView
From $54B to $85B: A Promising Decade for North America IVD - Business Upturn
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Imdx announces $26.0 million registered direct offering - marketscreener.com
Insight Molecular Diagnostics (IMDX) Secures $26M in Direct Stoc - GuruFocus
Insight Molecular Diagnostics prices $26M registered direct offering; shares down - MSN
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials - TipRanks
iMDx lines up $26M to expand GraftAssure into heart transplants - Stock Titan
iMDx Announces $26.0 Million Registered Direct Offering - Sahm
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Boston Scientific (BSX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Steris (STE) and Roche Holding AG (OtherRHHVF) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), NewAmsterdam Pharma Company (NAMS) and Resmed (RMD) - The Globe and Mail
Gastric Cancer Diagnostic Procedure Market to Grow at a CAGR of 6.53% - industrytoday.co.uk
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$8.13m - simplywall.st
Analysts Offer Insights on Healthcare Companies: BillionToOne, Inc. Class A (BLLN) and Dexcom (DXCM) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - marketscreener.com
Insight ‘congratulated’ STAR working group on organ health testing paper - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring - marketscreener.com
iMDx Announces 'JPM Week” and 'BTIG Snowbird” Conference Participation - The Manila Times
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of - GlobeNewswire
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - Sahm
Is Insight Molecular Diagnostics Inc. (7OC0) stock considered safe haven2026 world cup usa national team quarterfinals midfield engines low block defense group prediction preview - Улправда
Needham reiterates Buy rating on Insight Molecular stock, cites progress on GraftAssureDx - Investing.com Nigeria
Insight Molecular Diagnostics Inc. Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - marketscreener.com
Insight Molecular Diagnostics (IMDX) Nears Key FDA Submission Mi - GuruFocus
IMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - MarketScreener
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - Sahm
iMDx Stock Rebounds After-Hours As Study Shows Transplant Test Works As Well As Market Standard - MSN
Prostate Cancer Diagnostics Market Size Report, 2026 – 2035 - Global Market Insights Inc.
Insight Molecular Diagnostics Inc.Common Stock (NQ: IMDX - FinancialContent
KIFFIK Biomedical Closes Oversubscribed Series A to Advance Real-Time Molecular Diagnostics Platform - newarkadvocate.com
Insiders Rewarded With US$5.2m Addition To Investment As Insight Molecular Diagnostics Stock Hits US$183m - Yahoo Finance
Molecular Cytogenetics Market Analysis Reveals Growth - openPR.com
Insight Molecular (IMDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Insight Molecular Diagnostics (FRA:7OC0) EV-to-OCF : -5.98 (As of Dec. 24, 2025) - GuruFocus
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11% - simplywall.st
Animal Health Market Size, Share & Industry Trends Analysis Report [2032] - Fortune Business Insights
Why Insight Molecular Diagnostics Inc. (7OC0) stock attracts HNW investorsQuarterly Risk Review & Verified Short-Term Trading Plans - DonanımHaber
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Non sono disponibili dati finanziari per Insight Molecular Diagnostics Inc (IMDX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):